	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract
		X – Title.
		(b) Provide in the abstract an informative and balanced summary of what was done
		and what was found
		X – Abstract.
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
		X – Pgs. 4-5
Objectives	3	State specific objectives, including any prespecified hypotheses
		X – Pg. 5
Methods		
Study design	4	Present key elements of study design early in the paper
		X – Pgs. 6-7; Fig. 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment,
		exposure, follow-up, and data collection
		X - Pg. 6
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of
		selection of participants. Describe methods of follow-up
		X – Pg. 6 & 8
		(b) Cohort study—For matched studies, give matching criteria and number of
		exposed and unexposed
		n/a
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect
		modifiers. Give diagnostic criteria, if applicable
		X – Pgs. 9-10
Data sources/	8*	For each variable of interest, give sources of data and details of methods of
measurement		assessment (measurement). Describe comparability of assessment methods if there
		is more than one group
		X - Pgs. 6-10.
Bias	9	Describe any efforts to address potential sources of bias
		X - Pgs. 8-10.
Study size	10	Explain how the study size was arrived at
		X-Pg. 8
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable,
		describe which groupings were chosen and why
		X – Pg. 10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding
		X - Pg. 9; 20
		(b) Describe any methods used to examine subgroups and interactions
		X – Pg. 9 for subgroups.
		(c) Explain how missing data were addressed
		X – Pg. 10
		(d) Cohort study—If applicable, explain how loss to follow-up was addressed

$X-Pg.\ 10$ (missing data) and Pg. 11/ Fig. 2 loss to follow-up summarized

 (\underline{e}) Describe any sensitivity analyses

X - n/a.

Continued on next page

Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed		
		X - Pg. 10 and Fig 2		
		(b) Give reasons for non-participation at each stage		
		X – Fig 2 (select reasons); no reasons for LTFU were captured in the study.		
		(c) Consider use of a flow diagram		
		X – Fig 2		
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information		
data		on exposures and potential confounders		
		X – Pg. 11 & 12; Table 1, Supplemental Table 2 & 3		
		(b) Indicate number of participants with missing data for each variable of interest		
		X – Supplemental Tables 2,3,4,5.		
		(c) Cohort study—Summarise follow-up time (eg, average and total amount)		
		X – Fig 2 (mean duration FU not reported).		
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time		
		X – Pg. 12 & 14; Table 2, Fig 3; Supplemental Table 4 & 5		
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their		
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and		
		why they were included		
		X – Pg. 15-16, Fig 5 & Supp Fig 1.		
		(b) Report category boundaries when continuous variables were categorized		
		X-n/a		
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful		
		time period		
		X - n/a absolutes presented.		
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity		
		analyses		
		X - n/a		
Discussion				
Key results	18	Summarise key results with reference to study objectives		
•		X – Pg. 17-18		
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.		
		Discuss both direction and magnitude of any potential bias		
		X – Pg. 19-20		
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity		
		of analyses, results from similar studies, and other relevant evidence		
		X - Pg. 17-20		
Generalisability	21	Discuss the generalisability (external validity) of the study results		
		X – Pg. 17		
Other informati	on			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable,		
<u> </u>		for the original study on which the present article is based		
		X		

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.